Risk of cognitive decline progression is associated to increased blood-brain-barrier permeability: A longitudinal study in a memory unit clinical cohort

Introduction: This study examined the relationship between blood-brain-barrier permeability (BBBp), measured by cerebrospinal fluid/serum albumin ratio (QAlb), and cognitive decline progression in a clinical cohort. Methods: This prospective observational study included 334 participants from the BIO...

Full description

Bibliographic Details
Authors: Puig-Pijoan, Albert, Jiménez-Balado, Joan, Fernández-Lebrero, Aida, García-Escobar, Greta, Navalpotro-Gómez, Irene, Contador, José, Manero Borràs, Rosa María, Puente Periz, Victor Manuel, Suárez, Antoni, Muñoz López, Francisco José, 1964-, Grau, Oriol (Grau Rivera), Suárez-Calvet, Marc, Torre Fornell, Rafael de la, Roquer, Jaume, Ois Santiago, Angel Javier
Format: article
Status:Published version
Publication Date:2023
Country:España
Institution:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repository:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/58066
Online Access:http://hdl.handle.net/10230/58066
http://dx.doi.org/10.1002/alz.13433
Access Level:Open access
Keyword:Blood-brain barrier
Cerebrovascular disease
Cognition
Dementia
Vascular dementia
Description
Summary:Introduction: This study examined the relationship between blood-brain-barrier permeability (BBBp), measured by cerebrospinal fluid/serum albumin ratio (QAlb), and cognitive decline progression in a clinical cohort. Methods: This prospective observational study included 334 participants from the BIODEGMAR cohort. Cognitive decline progression was defined as an increase in Global Deterioration Scale and/or Clinical Dementia Rating scores. Associations between BBBp, demographics, and clinical factors were explored. Results: Male sex, diabetes mellitus, and cerebrovascular burden were associated with increased log-QAlb. Vascular cognitive impairment patients had the highest log-QAlb levels. Among the 273 participants with valid follow-up data, 154 (56.4%) showed cognitive decline progression. An 8% increase in the hazard of clinical worsening was observed for each 10% increase in log-QAlb. Discussion: These results suggest that increased BBBp in individuals with cognitive decline may contribute to clinical worsening, pointing to potential targeted therapies. QAlb could be a useful biomarker for identifying patients with a worse prognosis.

Similar Items